Related Experiment Video
Updated: Aug 15, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
CEA-based vaccines
Emina H Huang1, Howard L Kaufman
1Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Abstract:
Carcinoembryonic antigen (CEA), the first tumor-associated antigen to be described, was cloned in 1987 and is expressed on nearly 50% of all human tumors. The identification of T-cell specific epitopes within the coding region of the CEA protein has led to the development of various vaccine strategies that target CEA and CEA-expressing tumors. These vaccines have shown evidence of therapeutic effectiveness in animal models and are being evaluated in early phase clinical trials. Although trials are not designed to elucidate clinical responses, they have provided important information about the ability of individual vaccines to induce CEA-specific immune responses through the use of newer in vitro monitoring assays. Continued clinical testing in patients with less advanced disease and the administration of vaccines in combination with other standard therapy will help define the role of CEA-based vaccines in the treatment and prevention of human cancer.
Insights
Carcinoembryonic antigen (CEA) vaccines target tumors expressing this antigen. Early trials show these CEA-based vaccines can stimulate immune responses and are being explored for cancer treatment and prevention.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Carcinoembryonic antigen (CEA) is a tumor-associated antigen found in nearly 50% of human tumors.
- CEA was first cloned in 1987, establishing its significance in cancer research.
Purpose of the Study:
- To review the development and evaluation of vaccine strategies targeting CEA and CEA-expressing tumors.
- To discuss the role of CEA-specific immune responses and their monitoring in clinical trials.
Main Methods:
- Identification of T-cell specific epitopes within the CEA protein.
- Development and preclinical testing of CEA-based vaccines.
- Evaluation of vaccine-induced immune responses in early-phase clinical trials using in vitro assays.
Main Results:
- CEA-based vaccines have demonstrated therapeutic effectiveness in animal models.
- Early clinical trials are assessing the safety and immunogenicity of these vaccines.
- In vitro assays provide insights into the induction of CEA-specific immune responses.
Conclusions:
- CEA-based vaccines show promise for cancer treatment and prevention.
- Further clinical testing in less advanced disease and combination therapies are needed.
- Defining the role of CEA vaccines requires continued investigation in human cancer treatment.
Related Concept Videos
Cross-reactivity
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccines
Diphtheria
Encephalitis l: Introduction

